Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track IPSC with free AI briefings, catalyst countdowns, and dilution alerts.

IPSC · Century Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$174.1M Cash on Hand
24.8mo Cash Runway
Follow IPSC by email Get an email when IPSC reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about IPSC, unsubscribe in one click. Privacy

📣 What IPSC Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Allogeneic iPSC-derived Anti-CD19-CAR/IL-15-expr… Systemic Lupus Erythematosus Phase 1 · NCT06255028 Active not recruiting
Lymphodepleting Chemotherapy Systemic Lupus Erythematosus Phase 1 · NCT06255028 Active not recruiting

Also used in these trials (approved or third-party drugs, not IPSC's own candidates): Interleukin-2.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

IPSC holds $174.1M in cash and short-term investments (as of Sep 30, 2026) and burns about $21M/quarter from operations, an estimated runway of 24.8 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 30 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when IPSC files for a raise →

👥 Who Owns IPSC

Insiders 3.3% Other 5%+ holders 17% Institutions (135 holders) 79.7% Public and other holders 0%
HolderTypeShares% of sharesAs of
RA Capital Management, L.P. Institution (13G, 5%+) 17,944,649 9.88% 2026-01-09
Chen Yu 5%+ holder (13G) 17,754,430 9.78% 2026-01-09
Deep Track Capital, LP Institution (13G, 5%+) 13,486,400 7.43% 2026-01-08
RTW Investments, LP Institution (13G, 5%+) 13,043,478 7.18% 2026-03-31
Venrock Healthcare Capital Partners III, 5%+ holder (13G) 13,043,478 7.18% 2026-01-09
Commodore Capital LP Institution (13G, 5%+) 13,043,478 7.18% 2026-01-09
Brent Pfeiffenberger
President and CEO, Director · +945,000 options
Insider 3,633,839 2.00% 2026-09-11
Chad Cowan
Chief Scientific Officer · +265,000 options
Insider 1,186,019 0.65% 2026-06-11
Gregory Russotti
Title: Chief Technology and Manufacturin · +265,000 options
Insider 601,971 0.33% 2026-09-14
Douglas Carr
SVP Finance & Operations · +225,000 options
Insider 502,641 0.28% 2026-11-03

Share count 181,597,002 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full IPSC picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for IPSC and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.